Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro

Core Insights - Eli Lilly and Company (NYSE: LLY) is enhancing patient access to tirzepatide medications, including Zepbound and Mounjaro, through new Medicare initiatives [1][2][3] Group 1: Medicare Program Details - Starting January 1, 2027, tirzepatide treatments will be available through Medicare Part D plans, with out-of-pocket costs capped at $50 per month after the deductible is met [1] - The Medicare GLP-1 Bridge Model will be implemented from July 1, 2026, allowing eligible beneficiaries to access these medications for no more than $50 per month with no deductible during the initial six-month period [2] - For the 2027 rollout, cost-sharing will be limited to $245 per month plus a dispensing fee, providing immediate financial relief compared to traditional pricing structures [2] Group 2: Collaboration and Education Efforts - Eli Lilly is collaborating with health plans and providers to educate patients about their specific plan options, as some basic Medicare Part D plans may have varying cost-sharing requirements [3] - State Medicaid programs are invited to apply for participation starting May 1 on a rolling basis [3] Group 3: Company Overview - Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products in the US, Europe, China, Japan, and internationally [3]